Lantern Pharma Inc. (LTRN) Income Statement Analysis

See more : First Eagle Alternative Capital (FCRW) Income Statement Analysis – Financial Results

Complete financial analysis of Lantern Pharma Inc. (LTRN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Lantern Pharma Inc., a leading company in the Biotechnology industry within the Healthcare sector.

You may be interested

Whirlpool China Co., Ltd. (600983.SS) Income Statement Analysis – Financial Results
New Asia Construction & Development Corp. (2516.TW) Income Statement Analysis – Financial Results
Alpa Laboratories Limited (ALPA.BO) Income Statement Analysis – Financial Results
Changzhou Shenli Electrical Machine Incorporated Company (603819.SS) Income Statement Analysis – Financial Results
Ildong Pharmaceutical Co., Ltd. (249420.KS) Income Statement Analysis – Financial Results

Lantern Pharma Inc. (LTRN)

Industry: Biotechnology

Sector: Healthcare

Website: https://www.lanternpharma.com

About Lantern Pharma Inc.

Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, and prostate cancer. The company also develops LP-300 as a combination therapy for non or never-smokers with non-small cell lung cancer adenocarcinoma. In addition, its preclinical development drug candidate is LP-184, an alkylating agent that damages DNA in cancer cells that overexpress certain biomarkers or that harbor mutations in DNA repair pathways. Further, the company operates ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Additionally, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. The company was incorporated in 2013 and is headquartered in Dallas, Texas.

Metric	2023	2022	2021	2020	2019	2018
Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Cost of Revenue	174.84K	154.68K	97.42K	3.39K	1.63K	-2.54K
Gross Profit	-174.84K	-154.68K	-97.42K	-3.39K	-1.63K	2.54K
Gross Profit Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Research & Development	11.89M	8.60M	7.57M	2.24M	953.19K	572.10K
General & Administrative	5.98M	5.83M	5.02M	3.66M	1.48M	1.15M
Selling & Marketing	0.00	0.00	0.00	0.00	0.00	0.00
SG&A	5.98M	5.83M	5.02M	3.66M	1.48M	1.15M
Other Expenses	0.00	-31.55K	160.55K	0.00	0.00	0.00
Operating Expenses	17.88M	14.43M	12.59M	5.91M	2.43M	1.73M
Cost & Expenses	17.88M	14.43M	12.59M	5.91M	2.43M	1.73M
Interest Income	765.39K	204.36K	67.93K	0.00	0.00	0.00
Interest Expense	0.00	204.36K	0.00	0.00	0.00	0.00
Depreciation & Amortization	174.84K	154.68K	97.42K	3.39K	1.63K	-2.54K
EBITDA	-15.79M	-14.42M	-12.27M	-5.90M	-2.43M	-1.73M
EBITDA Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Income	-17.88M	-14.43M	-12.59M	-5.91M	-2.43M	-1.73M
Operating Income Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Total Other Income/Expenses	1.92M	172.81K	228.48K	0.00	0.00	0.00
Income Before Tax	-15.96M	-14.26M	-12.36M	-5.91M	-2.43M	-1.73M
Income Before Tax Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Income Tax Expense	0.00	-172.81K	-67.93K	-202.91K	-5.00	2.54K
Net Income	-15.96M	-14.09M	-12.30M	-5.91M	-2.43M	-1.73M
Net Income Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EPS	-1.47	-1.30	-1.13	-0.95	-0.39	-0.28
EPS Diluted	-1.47	-1.30	-1.13	-0.95	-0.39	-0.28
Weighted Avg Shares Out	10.84M	10.85M	10.90M	6.22M	6.27M	6.22M
Weighted Avg Shares Out (Dil)	10.84M	10.85M	10.90M	6.22M	6.27M	6.22M

Lantern Pharma Reports Fourth Quarter & Fiscal Year 2023 Financial Results and Business Highlights

March 18, 2024businesswire.com

DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (“AI”) company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning (“ML”) platform with multiple clinical-stage drug programs, today announced operational highlights and financial results for...

Lantern Pharma Announces Initial Patients Dosed in First-In-Human Clinical Trial for AI-Guided Drug-Candidate, LP-284

March 15, 2024businesswire.com

DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company developing targeted and transformative cancer therapies using its proprietary AI and machine learning (ML) platform, RADR®, with multiple clinical stage drug programs, today announced the dosing of the first...

Lantern Pharma to Report Fourth Quarter and Fiscal Year 2023 Operating & Financial Results on March 18th, 2024 at 4:30 p.m. ET

March 11, 2024businesswire.com

DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (“AI”) company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning (“ML”) platform with multiple clinical stage drug programs, today announced that it will host its...

Lantern To Participate in H.C Wainwright & Co.'s (HCW) 1st Annual Artificial Intelligence Based Drug Discovery & Development Virtual Conference

March 5, 2024businesswire.com

DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), a leader in AI-driven cancer drug discovery and development, announced that it will be presenting at a virtual conference being hosted by HCW. The conference will be on Thursday, March 7th, and is a...

Lantern Pharma Advances Unique ADC (Antibody Drug Conjugate) Program Across Multiple Solid Tumor Cancers

February 15, 2024businesswire.com

DALLAS--(BUSINESS WIRE)--Press release about Lantern Pharma's ADC program focused on cryptophycin drug-payload ADC being developed in collaboration with Bielefeld.

Starlight Therapeutics, a Subsidiary of Lantern Pharma Focused on CNS & Brain Cancers, Announces Dr. Marc Chamberlain as Chief Medical Officer

January 17, 2024businesswire.com

DALLAS--(BUSINESS WIRE)--Starlight Therapeutics— a Lantern Pharma (Nasdaq: LTRN) subsidiary focused exclusively on the clinical development of therapies for central nervous system and brain cancers with limited or no effective therapeutic options— today announced that Marc Chamberlain, M.D. has joined Starlight...

The 3 Most Undervalued AI Penny Stocks to Buy in December

December 13, 2023investorplace.com

It's easy to understand why investors remain curious about AI penny stocks in December and beyond. Leading companies in the artificial intelligence (AI) industry have multiplied in value in 2023.

FDA Grants Lantern Pharma Orphan Drug Designation for Drug Candidate LP-284 in High-Grade B-cell Lymphomas (HGBL)

November 30, 2023businesswire.com

DALLAS--(BUSINESS WIRE)--FDA Grants Lantern Pharma Orphan Drug Designation for Drug Candidate LP-284 in High-Grade B-cell Lymphomas (HGBL). This is the second ODD for LP-284.

Lantern Pharma Inc. (LTRN) Q3 2023 Earnings Call Transcript

November 9, 2023seekingalpha.com

Lantern Pharma Inc. (NASDAQ:LTRN ) Q3 2023 Earnings Conference Call November 8, 2023 4:30 PM ET Company Participants Panna Sharma - President and Chief Executive Officer David Margrave - Chief Financial Officer Conference Call Participants Operator Good afternoon, and welcome...